LivaNova (NASDAQ:LIVN) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of LivaNova (NASDAQ:LIVN) in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a $72.00 price target on the stock.

A number of other research firms have also recently issued reports on LIVN. Barclays raised their price target on shares of LivaNova from $57.00 to $61.00 and gave the stock an equal weight rating in a report on Monday, February 26th. Mizuho reissued a buy rating and set a $75.00 target price on shares of LivaNova in a report on Wednesday, March 27th. StockNews.com raised shares of LivaNova from a hold rating to a buy rating in a report on Thursday, April 25th. Finally, Robert W. Baird raised their target price on shares of LivaNova from $56.00 to $62.00 and gave the stock a neutral rating in a report on Thursday, February 22nd. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, LivaNova currently has a consensus rating of Moderate Buy and a consensus target price of $64.40.

LivaNova Trading Up 12.3 %

NASDAQ LIVN opened at $62.62 on Wednesday. The company has a fifty day simple moving average of $54.44 and a two-hundred day simple moving average of $50.85. The stock has a market cap of $3.39 billion, a P/E ratio of 195.69 and a beta of 0.89. LivaNova has a 12-month low of $42.75 and a 12-month high of $63.21. The company has a current ratio of 2.95, a quick ratio of 2.51 and a debt-to-equity ratio of 0.44.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.10. The business had revenue of $310.10 million during the quarter, compared to analysts’ expectations of $287.65 million. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The business’s quarterly revenue was up 12.8% on a year-over-year basis. During the same quarter last year, the company posted $0.81 earnings per share. On average, analysts forecast that LivaNova will post 3.01 earnings per share for the current year.

Institutional Trading of LivaNova

Institutional investors have recently modified their holdings of the stock. Headlands Technologies LLC acquired a new stake in shares of LivaNova in the third quarter valued at about $72,000. Picton Mahoney Asset Management acquired a new stake in shares of LivaNova in the third quarter valued at about $91,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of LivaNova in the third quarter valued at about $217,000. AlphaMark Advisors LLC acquired a new stake in shares of LivaNova in the third quarter valued at about $244,000. Finally, Jump Financial LLC acquired a new stake in shares of LivaNova in the third quarter valued at about $273,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.